AVBP (ArriVent BioPharma) Moat Score: 2/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVBP ArriVent BioPharma Inc AVBP
12 GF Score
Price $32.54
! 2 Warning Signs
View Full Analysis

What is ArriVent BioPharma Moat Score?

ArriVent BioPharma AVBP -3.27% 12 Moat Score is 2 as of Jul. 15, 2026. GuruFocus rates AVBP with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, ArriVent BioPharma ranks better than 58.31% on this metric.

ArriVent BioPharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

ArriVent BioPharma has No Moat: ArriVent BioPharma operates in a competitive biotech sector with limited market share and no significant intellectual property or regulatory advantages. The company lacks strong brand recognition and customer loyalty, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ArriVent BioPharma might have No Moat - Very weak/transient advantages.

ArriVent BioPharma  (NAS:AVBP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ArriVent BioPharma Moat Score Related Terms

AVBP vs MAZE, DMRA, AKTS: Moat Score Comparison

For the Biotechnology subindustry, ArriVent BioPharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArriVent BioPharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Moat Score distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Moat Score falls into.


AVBP
12GF Score
ArriVent BioPharma Inc AVBP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
ArriVent BioPharma (AVBP) has a Moat Score of 2 as of Jul. 15, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, ArriVent BioPharma ranks #582 out of 1396 companies in the Biotechnology industry, placing it in the top 41.7%.
Is ArriVent BioPharma's Moat Score too high?
ArriVent BioPharma's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. ArriVent BioPharma's value of 2 is 0% at this industry median. Based on the distribution chart, ArriVent BioPharma ranks #582 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ArriVent BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does ArriVent BioPharma's Moat Score compare to MAZE and DMRA?
According to the Biotechnology industry distribution chart, ArriVent BioPharma ranks #582 out of 1396 companies for Moat Score. This puts ArriVent BioPharma in the upper half of its industry. The industry median Moat Score is 2.00. ArriVent BioPharma's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ArriVent BioPharma's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArriVent BioPharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArriVent BioPharma stock overvalued right now?
ArriVent BioPharma (AVBP) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. ArriVent BioPharma's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For ArriVent BioPharma (AVBP), the current Moat Score is 2 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ArriVent BioPharma Business Description

Address 18 Campus Boulevard, Suite 100, Newtown Square, PA, USA, 19073
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
12GF Score

Get the complete analysis for AVBP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.54
Price